China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment space with the establishment of a new industry fund. This fund is designed to target opportunities in the life sciences and healthcare sectors. In a collaborative effort, Baheal will be partnering with a consortium that includes Suzhou Capital Group, Suzhou Industrial Park Entrepreneurship Investment Guidance Fund, and the Institute of Systems Medicine, Chinese Academy of Medical Sciences, along with its Suzhou counterpart.
While specific financials of this strategic move have not been disclosed, the fund is poised to concentrate on early-stage investment and incubation in biomedicine and medical device sectors. It also aspires to catalyze translational research and facilitate product industrialization, capitalizing on scientific breakthroughs from research institutions. Baheal Pharmaceutical Group is slated to assume a managerial role within the fund, guiding its investment strategy and operations.- Flcube.com
